Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ctively, based on weighted average shares outstanding of 17.6 million and 17.5 million, respectively.

Cash equivalents and short-term investments were approximately $57.0 million at September 30, 2009, compared to $13.4 million at June 30, 2009. The increase reflects the receipt of a $48.8 million upfront payment from Astellas received in July 2009.

Stephen Ghiglieri, CFO, commented, "The third quarter of 2009 represents the first time we have reported quarterly revenue, which marks a milestone for NeurogesX. Our balance sheet is also strongly positioned with $57 million in cash, cash equivalents and short term investments. Consistent with our spending guidance for 2009, we are continuing our conservative focus in advance of our upcoming PDUFA date. As a result of that focus, we have been investing in commercialization activities that require long lead times, such as setting up the distribution channel, that are necessary to implement now to be ready for our targeted first half 2010 launch. Major investments, such as sales force deployment, are still being deferred pending FDA approval of Qutenza. We are also exploring strategies to further strengthen our balance sheet ahead of a potential U.S. Qutenza launch."

Development Update

NeurogesX is advancing its planning for NGX-1998 and expects to re-initiate clinical development activities in 2010.

Conference Call Details

The Company will hold its quarterly conference call today at 9:00 a.m. ET (6:00 a.m. PT) to discuss third quarter 2009 results.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

A replay of the conference call will be available beginning November 6, 2009 at 7:30 p.m. ET (4:30 p.m. PT) and endi
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... MA (PRWEB) October 30, 2014 ... and collaboration provider, offers Office 365 end users ... into a complete phone system by adding voice ... 365 (O365) includes Lync Online, a communication tool ... Lync calls. With hosted voice, O365 becomes a ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 James Sherley says ... in adult tissue stem cell technology since his days as ... in Philadelphia in the late 1990’s. Sherley founded the ... The company holds all the intellectual property developed in Sherley’s ... at the Massachusetts Institute of Technology (MIT), and more recently ...
(Date:10/30/2014)... NY (PRWEB) October 30, 2014 Whitehouse ... for its ICH Stability Testing and Package Test Capacity. ... investment centers on a dramatic increase in environmental chamber ... of stability, storage and aging samples to be securely ... of this major capital expenditure has already taken place ...
(Date:10/30/2014)... October 30, 2014 Grace Century portfolio project, ... A. Manganello, Chairman of the Board, to the National ... The appointment was made by the Ministry of Health on ... 2014. , More than a year after Bahamian ... , Prime Minister Perry Christie said the government has completed ...
Breaking Biology Technology:SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
... Microchip,Biotechnologies, Inc. (MBI) is pleased to announce that ... Biodiversity Institute of Ontario,University of Guelph, will be ... for the Apollo 100 STAR System. The Apollo ... system for DNA sample preparation for,sequencing. The System ...
... Remergent Skincare Line, FREEPORT, N.Y., April 8, ... the development and sale of skincare,products utilizing DNA ... investment round led by existing investor Trevi Health ... new capital is being used to fund the ...
... 8 Amsterdam,Molecular Therapeutics (Euronext: AMT), a leader in ... part of the newly created Next Biotech Index of,NYSE ... our company,for this index," said Ronald Lorijn, CEO of ... companies and will help investors to track,the performance of ...
Cached Biology Technology:Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing 2Amsterdam Molecular Therapeutics Part of Next Biotech Index 2
(Date:10/29/2014)... unconventional oil and gas production are well over recommended ... open access journal Environmental Health . High levels ... study is the first to be based on community ... could be used to supplement official air-quality monitoring programs. ... do not readily flow to the surface. This is ...
(Date:10/29/2014)... New research presented at the Society for ... TX showed for the first time that it ... using a readily available nutritional supplement, AHCC. ... Judith A. Smith, Pharm.D., associate professor in the ... The University of Texas Health Science Center at ...
(Date:10/29/2014)... their food, but they also need protection from its harmful ... of molecules in plants that shields them from sun damage. ... American Chemical Society , one team reports on the mechanics ... and colleagues at Purdue University note that the harsh ultraviolet ... to plant DNA and, as a result, hinder plant growth. ...
Breaking Biology News(10 mins):Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
... today by the European Commission,s in-house science service, the Joint ... business managers on how to assess the environmental impacts of ... a resource-efficient Europe and aims to help design more sustainable ... people and limited resources. , The increasing world population ...
... 15, 2012) This fall, Drexel Environmental Science students will ... locally and across the globe as a result of ... Natural Sciences. Out of the affiliation comes the Department ... will work and learn among some of the world,s ...
... is the most common type of liver disease in the ... NAFLD is often associated with obesity and other parameters ... factor for the development of cardiovascular disease. In a ... that modest alcohol consumption (an average of up to 20 ...
Cached Biology News:A practical guide to green products and services 2New museum-university partnership ushers in new era of environmental science education 2
Polyclonal Antibody to CRTR-1...
Recognizes NSCL1. The molecular weight of the protein is 14,616 Daltons....
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
Biology Products: